Anti-Infective R&D Ecosystem Getting Healthier, But Trials Remain

FDA and other government agencies have successfully nurtured a healthy ecosystem to rebuild the antibiotics pipeline, and a new crop of antibiotics has now reached the pivotal stage of clinical trials. But the sponsors are largely small companies: can they survive in the highly constrained commercial market for serious infections?

A healthy ecosystem supporting research and development of new anti-infectives is emerging with the considerable help of government efforts to address the threats of spreading antimicrobial resistance.

Twenty new antimicrobial products have come through FDA's Qualified Infectious Disease Products program and are in or preparing for Phase...

More from Clinical Trials

More from R&D